ESMO-WCGI 2020. Early "dramatic": Apatinib in combination with TACE could bring potential benefits to patients with recurrent HCC.

Introduction: the latest application progress of apatinib in recurrent liver cancer.the 22nd European Society of Oncology (ESMO) World Congress of Gastroenterology (wcgi) in 2020 will be held online from July 1 to 4. As an important global academic conference in this field, esmo-wcgi will bring together world-renowned experts in gastroenterology, oncology, Hepatology and pathology, as well as researchers from all over the world, to share and discuss the key issues in this rapidly developing scientific field The latest data and pioneering research are dedicated to improving the lives of patients with gastrointestinal cancer.the related research progress report in the field of liver cancer is an important part of esmo-wcgi. Associate Professor Zheng Lu, Department of hepatobiliary surgery, Xinqiao Hospital, Military Medical University of China, will conduct a "efficient and safety of TACE with and without apatinib for recurrent hepatocellular carcinoma: a prospective randomized controlled trial" [efficacy and safety of transcatheter arterial chemoembolization (TACE) in combination with or without apatinib in the treatment of recurrent hepatocellular carcinoma: a prospective randomized controlled trial] will be presented in this paper.hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. It has a high risk of postoperative recurrence and seriously affects the prognosis of patients.transcatheter arterial chemoembolization (TACE) is a commonly used treatment method with good tolerance and low hepatotoxicity. It can benefit patients with recurrent liver cancer (especially liver function score & lt; = 7), but the overall effect is still not ideal.apatinib is a novel oral small molecule tyrosine kinase inhibitor, which can effectively inhibit tumor angiogenesis and tumor proliferation, and has shown good therapeutic potential in advanced HCC.however, for HCC patients with recurrence after hepatectomy, the efficacy and safety of TACE combined with apatinib and TACE alone are still lacking.therefore, Zheng Lu's team explored this in a prospective randomized controlled trial (RCT).from January 2018 to January 2020, a total of 80 HCC patients who relapsed after hepatectomy and were unwilling / unable to undergo re operation or liver transplantation were enrolled in the study. They were randomly treated with TACE combined with apatinib (n = 40) or TACE alone (n = 40).patients in TACE combined with apatinib group received apatinib 500mg once a day during routine on-demand TACE treatment.clinical information of patients was collected during the study and all participants were followed up until ttup or the end of the study.the outcome measures included progression free survival (PFS), overall survival (OS), adverse events (AES), and objective response rate (ORR) and disease control rate (DCR) based on mrecist criteria (American Association for the study of liver diseases, 2008), of which PFS was the primary endpoint.the oral report of Associate Professor Zheng Lu on esmo-wcgi will share with us the results of this study and the application value of apatinib in anti-tumor treatment. Let us wait and see.apatinib (yn968d1) is an oral small molecule tyrosine kinase inhibitor, which can selectively inhibit VEGFR2 (also known as KDR).it can inhibit the migration and proliferation of endothelial cells mediated by VEGF, thus preventing the formation of new blood vessels in tumor tissues.the structural formula of apatinib, Wikipedia apatinib is a national class 1.1 innovative drug with independent intellectual property rights, which was developed by Jiangsu Hengrui pharmaceutical for more than 10 years. As a potential research cancer drug for the treatment of metastatic gastric cancer, metastatic breast cancer and advanced liver cancer, a number of studies are under way.apatinib was approved by China's State Drug Administration in October 2014 for the treatment of patients with advanced gastric cancer, and it was included in the national health insurance list through negotiation in 2017. the application of apatinib in the field of liver cancer can be traced back to 2014 American Society of Clinical Oncology (ASCO) conference, a phase II study published by Professor Qin Shukui showed that apatinib has potential survival benefits for patients with advanced HCC. the oral presentation by Professor Qin Shukui at ASCO 2020 once again demonstrated the results of a randomized controlled double-blind phase III study on second-line treatment of advanced HCC. Compared with placebo, apatinib significantly prolonged overall survival (OS) and progression free survival (PFS), with a median OS of 8.7 and 6.8 months, a risk ratio (HR) of 0.785 and a 95% confidence interval (CI) of 0.785 ）The median PFS were 4.5 and 1.9 months, HR was 0.471, 95% CI was 0.369-0.601, and the safety was controllable. references (slide up and down) 1 efficiency and safety of TACE with and without apatinib for recurrent hepatocellular carcinoma: a prospective randomized controlled trial. 2 apatinib in Chinese patients with advanced hepatocellular carcinoma: a phase II randomized, open label trial. Doi: 10.1200/jco.2014.32.15_ suppl.4019.4 Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study. DOI: 10.1200/JCO.2020.38.15_ Supply.4507 source: for more information, please click read the original to download the meis medical app~